

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)

Index

- acetylcholine 2, 3, 9, 10, 12, 15–17, 21, 45, 66, 114, 175, 176, 180, 182, 202, 211, 231, 250, 297, 301, 302. *See also* botulinum toxin: mechanism of action
- achalasia 64, 283, 318
- Action Research Arm Test 152
- acupuncture 87
- acyclovir 177
- adenosine triphosphate (ATP) 301
- adenovirus 40
- adipocytes, effect of botulinum toxin on 38
- adrenergic agonists and antagonists
 α - 294, 297, 334, 350
 β - 230, 361. *See also* specific drug
- adrenoreceptors 303
- AIDS 85
- akinesia 204
- alcoholism 317
- alfuzosin 295
- Allergan, Inc. 4, 28, 29, 33, 59, 252, 256, 288, 309, 313
- allergies, treatment with botulinum toxin 39
- alpha-bungarotoxin 262, 263
- amantadine 361
- amblyopia 265
- American Urological Association (AUA)
 symptom index 293, 295, 297
- amino acid disorders 85
- aminoglycoside antibiotics 75, 255
- aminoquinoline antimalarial compounds 74
- ammonium chloride 15
- amyotrophic lateral sclerosis (ALS) 204, 220
- anal
 disorders and their treatment 298–311
 fissure 64, 283, 303–11
 haemorrhoidectomy 316
 pain 315
 sphincter. *See* sphincter: external anal (EAS); sphincter: internal anal (IAS)
 tone 299
- analgesics 5, 6, 177, 230, 231, 246, 247, 250. *See also* codeine; morphine; opioids; paracetamol; pain: anaesthesia for
- anhidrosis 181. *See also* euhydrosis; hyperhidrosis
- anismus 65
- antibodies for botulinum toxin. *See* immunoresistance to botulinum toxin
- anti-cholinergic drugs 80, 87, 88, 180, 207, 361
- anticoagulants 264
- anticonvulsants 230, 247
- antidepressants 177, 230, 247, 351
- apraclonidine hydrochloride (IOPIDINE®) 334
- apraxia of eye opening 6, 275–6
 as cause of abnormal neck posture 87
 definition of 275
 non-response to botulinum toxin 275
- Artefill® 345, 346
- Ashworth Scale 73, 138, 145, 148, 149, 151–4
- assays for botulinum toxin. *See* botulinum toxin: assay
- atrial natriuretic peptide 175
- atropine 11, 180, 208
- attention deficit hyperactivity disorder (ADHD) 350, 351
- baclofen 80, 88, 128, 134, 135, 138, 141, 368. *See also* gamma-aminobutyric acid (GABA)
- back pain
 activity modification for 246
 analgesics for 246
 anaesthetics for 249
 bed rest for 245
 botulinum toxin for 28, 245, 250–1, 253–5
 diagnosis and assessment 245, 255
 economic costs of 1, 244
 from acute muscle spasms 66
 management of 244
 muscle relaxants for 247
 percutaneous radiofrequency neurotomy for 249
 physical therapy for 248–9
 prevalence of 243
 steroids for 249
 surgery for 249
 trigger points in 253–6. *See also* neck: pain
- basal ganglia, in cervical dystonia 80
- Bean strain of botulinum toxin 33

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**376** Index

- Beck Depression Inventory score 236
- benzodiazepines 80, 88, 132, 135, 137
- bentropine mesilate 208
- Berg Balance scale 152
- Bier's nerve block 184, 187
- biological warfare/bioterrorism using botulism 2–27
- bladder, urinary
 - anatomy and physiology 282–6
 - botulinum toxin treatment for disorders of 6, 45, 72, 287, 289–91, 293
 - compliance 289
 - filling 282
 - hyper-reflexia 64
 - incontinence 290, 291, 294
 - neural control of 284, 286
 - over active 22
 - surgical treatment for disorders of 289
 - urethral obstruction and 294
 - urethral pressure and 287, 289
 - urine retention in 88, 295, 297
 - urine storage in 283, 287, 290, 297
- blepharospasm 3, 263
 - as side effect of botulinum toxin treatment 237
 - atypical (pretarsal) 274, 275
 - baclofen treatment for 88
 - botulinum toxin treatment for 3, 4, 6, 28, 54, 60, 61, 263, 273, 274
 - idiopathic 61, 274–5
 - lack of immunoresistance in 274
 - surgery for 276
 - treatment side effects 275
 - typical 274. *See also* apraxia of eye opening
- BoNT-A 29, 35, 59. *See also* botulinum toxin
 - type A; China: type A toxin products from
- BOTOX®
 - antigenicity of 47, 48
 - characteristics of 65
 - dosage 60, 73, 99, 117–19, 183, 188, 192
 - dose ratios with Dysport® 60–2, 141
 - efficacy 48
 - formulation 73
 - for glabellar lines 330–4. *See also* glabellar area
 - history 1–2, 4, 28
 - immunogenic load of 67
 - indications for 199
 - licensing 3
 - molecular characteristics of 33, 59
 - off label indications 329
 - safety of 48
 - side effects 73–4
 - units 5
 - uptake of 141. *See also* botulinum toxin; botulinum toxin type A; *specific disorder*
- botulinum toxin
 - activation of 9
 - adjunctive fillers for 330, 338, 340, 342, 343, 345–7
 - administration (injection) of 15, 35, 45, 67–73, 75–6, 98, 100, 187, 213–19, 237–9, 255, 329, 341–2
 - analgesic effects 5, 6, 231
 - antibodies. *See* immunoresistance to botulinum toxin
 - antigenicity 45, 47
 - assay 30–1, 50, 53. *See also* specific assays
 - Bean strain 33
 - bulking agent for 34
 - commercial development and production 4, 59, 62–6. *See also* botulinum toxin: manufacturing processes
 - complexes 3, 5, 29, 36, 59, 76
 - contraindications 74, 255
 - cost 62, 65, 66
 - cross-reactivity between serotypes 49
 - delivery vectors 38, 40
 - diffusion 218, 220, 264, 267, 310, 330, 331, 333, 336, 338, 342. *See also* side effects
 - diffusion margin 63, 74
 - dilution 68–70, 99, 328–9, 341, 370
 - disposal 72
 - dosage 60, 61, 73, 91, 99, 119, 189, 193, 214–17, 219, 232, 236, 256, 291, 336, 351, 363, 366. *See also* specific disorder
 - dose modifiers 100
 - duration 15, 21, 30, 73, 185, 191, 212, 214–17, 277
 - efficacy 21, 49, 183, 212, 214–17, 231, 233, 234, 239, 290, 352
 - evolution 27
 - for acute daily headache 234
 - formulation 34–6. *See also* botulinum toxin
 - Type A: formulation; botulinum toxin
 - Type A: formulation
 - fragments, engineering of 36, 39
 - haemagglutination activity 29
 - heavy chain 39–40
 - history as a therapeutic agent 2–3, 7, 22
 - idiopathic 61, 274–5
 - immunoassays for 30
 - immunoresistance. *See* immunoresistance to botulinum toxin
 - indications for 1, 64, 66
 - ¹²⁵Iodine labelled 14, 15
 - lethal dose 34, 35
 - licensing 66
 - light chain 37–8, 40
 - manufacturing processes 29, 31–3, 67
 - mechanism of action 9–18, 31, 35, 37–9, 45, 114, 231, 250, 262, 282
 - media and 7
 - molecular characteristics of 59
 - myoclonus 7, 352–5
 - non-neuronal actions 38
 - ophthalmologic uses for. *See* ophthalmologic disorders
 - optimal pH for 59
 - patient access to 66
 - physiological action of 3
 - potency 38, 45

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)

377

Index

- preservatives in 34
- production by bacteria. *See Clostridium botulinum; Clostridium butyricum; Clostridium baratii*
- purification 36
- as a research tool 10
- resistance. *See* immunoresistance to botulinum toxin
- reversibility 72
- safe handling of 10
- safety of 74–5, 152, 239
- safety margin 63, 74
- serotypes 6, 9, 12, 29, 39, 49, 59–62, 65, 93, 250. *See also specific serotypes*
- shelf life 17, 34, 35. *See also* botulinum toxin: storage
- side effects 72, 93–5, 99, 116, 180, 181, 184, 189, 193–4, 211, 214–17, 220–1, 232, 257, 264, 275, 334, 352
- stabilizing agent in 34
- storage 66–7. *See also* botulinum toxin: shelf life
- structure 9, 17, 36–8
- therapeutic ratio 35
- uptake 15, 75
- for urinary tract disorders 296, 297, 299
- as a vaccine 2, 6. *See also* BOTOX®; botulinum toxin type A; botulinum toxin type B; serotypes of botulinum toxin
- botulinum toxin treatment for
 - allergies 39
 - back pain 28, 245, 250–1, 253–5
 - bladder disorders 6, 45, 72, 287, 289–91, 293
 - blepharospasm 3, 4, 6, 28, 54, 60, 61, 263, 274, 295
 - cervical dystonia 3, 28, 46–8, 51, 60, 64, 72, 80, 81, 86–7, 91–3, 95–102
 - cosmetic uses. *See* face: treatment of
 - drooling 211–21
 - facial wrinkle lines 7, 28, 231, 331. *See also* glabellar area
 - gastrointestinal disorders 22, 45, 64, 72, 283, 311
 - glabellar lines 28, 65, 72
 - headache 231, 236–9
 - hemifacial spasm 3, 4, 28, 64, 72, 276–7
 - hyperhidrosis 22, 28, 35, 72, 180, 182–8, 190, 191, 193, 213, 231, 329
 - hypersalivation 6, 22
 - migraine headache 28, 64, 237, 239
 - pain 231, 236–7, 250
 - pancreato-biliary disorders 317
 - Parkinson's disease for 7, 357–60
 - spasticity 69, 123, 127, 134, 141, 143, 146, 155
 - strabismus 3, 5, 27, 28, 64, 263–9
 - tears 279
 - tics 65, 350–2
 - tremor 7, 361–4
 - whiplash 249, 252–3
- botulinum toxin type A
 - approved indications 29
 - assays 30
 - as first-choice therapeutic 10
 - commercial sources for 3, 5
 - cosmetic uses. *See* face: treatment of
 - dosage. *See* botulinum toxin: dosage
 - duration of 17, 185
 - endocrine cells responses to 15
 - for acute daily headache 235
 - for migraine headache 231
 - formulation 28, 30, 34
 - from Centre for Applied Microbiology and Research 28
 - gene for 33
 - manufacturing specifications for 33
 - non-responders to 29
 - peripheral cholinergic specificity of 10
 - potency relative to botulinum toxin type B 212
 - specificity of 21
 - targets of 19. *See also* botulinum toxin; Xeomin
- botulinum toxin type B
 - approved indications for 29
 - distribution 29
 - dosage. *See* botulinum toxin: dosage
 - effect on mammalian nerve endings 10, 12
 - for cervical dystonia treatment 93
 - for drooling 213
 - formulation 29
 - for hyperhidrosis 192–3
 - for pain management 251
 - gene for 33
 - history of 3, 5
 - manufacturing 29
 - side effects of 93. *See also* BOTOX®
- botulinum type C 29, 49
- botulinum type E 19, 29, 49
- botulinum type F 19, 29, 49, 54, 191
- botulism
 - biological warfare and 27
 - cause of 27. *See also* *Clostridium botulinum*
 - epidemiology of 33
 - history of 1, 2, 211
 - immunization to 45, 46. *See also* immunoresistance to botulinum toxin
 - in drug users 27
 - infant/childhood 27, 46
 - neurotoxins of. *See* botulinum toxin
 - prevention of 46
 - symptoms of 12, 21, 37
 - wound 27
- bowel. *See* gastrointestinal tract
- brow
 - fillers for 338
 - lift 335, 338. *See also* face: treatment of
- bruxism 65
- calcitonin gene related peptide (CGRP) 175, 231
- calcium channel blockers 230, 351
- calcium hydroxylapatite (Radiess®) 345, 347
- calmodulin 302
- calponin 302
- cannabis 138
- carbamazepine 247

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**378** Index

- catecholamines 15
- cation channels 9
- Centre for Applied Microbiology and Research (CAMR) 4, 28
- cerebellar granule cells 19
- cerebral palsy
 - BOTOX® for 3, 64
 - guidelines for treating 75, 205
 - in children 6, 205
 - spasticity in 122
- cervical dystonia
 - aetiology of 80, 85–6
 - botulinum toxin for 3, 28, 46–8, 51, 60, 64, 72, 80, 81, 86–7, 91–3, 95–102
 - classification of 5, 80–4
 - diagnosis 84–6
 - disability from 82, 83
 - dosage recommendations for 61, 99
 - dosages of botulinum toxin for 60
 - Dysport® use for 28, 80
 - epidemiology 81, 84
 - indications for botulinum toxin treatment 95
 - management of 5
 - muscles commonly involved in 14
 - natural history of 81
 - non-botulinum toxin treatments for 87–9
 - prevalence 61, 81
 - provocative and palliative factors in 83
 - rating scales for 100
 - remission and relapse of 81
 - resistance to botulinum toxin therapy in 80, 87, 92–3
 - social embarrassment from
 - symptoms of 81, 82, 86
 - surgical treatment for 81, 89–91
- China, type A toxin products from 29, 35, 59
- cGRP 15
- chloroquine 74
- cholelithiasis 317
- chromaffin cells 19
- chromhidrosis 191, 192. *See also* hyperhidrosis
- chronic pain. *See* pain: chronic
- Clinical Standards Advisory Group (CSAG) 243–5
- clonazepam 88, 351, 354, 356, 368
- clonidine 351
- Clostridium barati* 9
- Clostridium botulinum* 1, 2, 9, 27, 33, 36, 67, 250. *See also* botulinum toxin:
 - manufacturing processes
- Clostridium butyricum* 9
- clozapine 89, 204, 208, 213
- cocaine 330
- codeine 246
- collagen 345, 347
- compound muscle action potentials (CMAPS) 52
- computed tomography (CT) 71, 86, 143
- constipation 64, 88, 292–4, 312–14. *See also* anal disorders and their treatment; Parkinson's disease
- convergent squint 264
- Corynebacterium* 192
- cosmetic uses. *See* face: treatment of
- Cosmoderm® 345, 346
- cramps
 - occupational 366–70
 - writer's 7, 64, 366–9
- Creutzfeldt–Jakob disease 85
- dantrium 368
- dantrolene sodium 134–6
- deep brain stimulation (DBS) 90, 91
- Dermatology Life Quality Index 179
- desipramine 3
- diabetes 177, 189, 190, 356
- diazepam 247, 356
- diffusion margin for botulinum toxin 63, 74
- Digit Abduction Score (DAS) 74
- di-isopropylfluoro-phosphate 262, 263
- diphtheria toxin 40
- diplopia 237, 269, 338
- Disability Assessment Scale (Score) 73, 151–4
- D-penicillamine 361
- dopamine 15, 89
 - depleting agents 89
 - receptor agonists and antagonists 86, 88, 89, 351
 - release of 15
 - replacement therapy 357. *See also* Parkinson's disease
- dot blot in vitro assay 53
- doxazosin 294, 295
- drooling 211–21
 - and botulinum toxin side effects 211
 - causes of 204, 205
 - clozapine-induced 204, 208, 213
 - definition of 201
 - evaluation 205, 206
 - in infants and children 6, 204, 217
 - non-toxin treatments for 207–10
 - persistent 205
 - prevalence of 204
 - secondary to parkinsonism 208
 - surgery for 208, 209
 - swallowing reflex and 201. *See also* saliva: production rate
- Drool Rating Scale (DRS) 206, 225–8
- Drooling Frequency Scale (DFS) 206, 225
- Drooling Severity Scale (DSS) 206, 225
- Duncan-Elie test, for rectus muscle 144
- dysaesthesia 140
- dyskinesias. *See specific syndrome*
- dyspareunia 298
- dysphagia 69, 73, 93, 94, 193, 212, 220, 329, 344, 362
- dysphonia 95
- dyspnea 95
- Dysport®
 - characteristics of 65
 - for adductor laryngeal dystonia 116
 - for blepharospasm 3, 28
 - for chronic tension headache 236
 - dosage 5, 60, 99, 117–19, 183, 190, 191, 358, 363

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**379 Index**

- dose ratios with BOTOX® 60–2, 141
- efficacy 183
- for hemifacial spasm 3, 28
- for hyperhidrosis 183
- for Parkinson's disease 358
- for spasticity 3
- for strabismus 3, 28. *See also* botulinum toxin;
- botulinum toxin type B
- history of 4
- molecular characteristics of 59
- side effects of 72, 116
- storage 67
- dystonia
 - botulinum toxin for 366
 - definition of 80, 111
 - dopa-responsive 89
 - focal 28, 64, 82, 365–6. *See also* cervical dystonia
 - guidelines for treating 75
 - idiopathic 83, 84, 86
 - jaw closing 112, 119
 - jaw opening 112, 117–19
 - laryngeal 111–16
 - limb 7, 365–70
 - pain treatment for 231
 - palatal myoclonus 112, 120
 - slewed jaw 112, 119–20
 - spasmodic 64
 - tongue 112, 113, 116–18
- Elan Pharmaceuticals 5, 29, 33, 59, 193, 309
- electromyography guidance 71, 102, 115, 142, 147, 151, 262, 358, 363, 365–7, 369
- encephalomyelitis 356
- encephalopathy 205
- endocytosis 10, 14, 15, 59
- endoscopic retrograde pancreatography (ERCP) 318
- endoscopic thoracic sympathectomy (ETS) 181, 182
- enteric nervous system (ENS) 282, 299–303
- entropion 278, 279
- enzyme-linked immunosorbent assay (ELISA) 53
- Erythrina cristagalli* 39
- estropia 264–8
- euhydrosis 179–81
- evaluation scales
 - Action Research Arm Test 152
 - Ashworth Scale 73, 138, 145, 148, 149, 151–4
 - Beck Depression Inventory score 236
 - Dermatology Life Quality Index 179
 - Digit Abduction Score (DAS) 74
 - Disability Assessment Scale (Score) 73, 151–4
 - Drool Rating Scale (DRS) 206, 225–8
 - Drooling Frequency Scale (DFS) 206, 225
 - Drooling Severity Scale (DSS) 206, 225
 - Duncan-Elie test 144
 - Extensor Digitorum Brevis Test (EDB) 52
 - Frontalis-Type A Test (F-TAT) 50–2
 - Fugl-Meyer Motor Assessment Score 152
 - Functional Independence Measure 150
 - Health Related Quality of Life Measures (HR-QoL) 275
- Hospital Anxiety and Depression Scale (HAD) 252
- Hyperhidrosis Disease Severity Scale (HDSS) 179, 180
- Hyperhidrosis Impact Questionnaire (HHIQ) 179
- Jebsen Taylor Hand test 152
- Likert Scale 152
- Minor starch iodine test 179, 182, 183, 188, 189, 191, 208
- Mouse Diaphragm Assay (MDA) 47, 50, 52, 53. *See also* Mouse Protection Assay (MPA)
- Mouse Protection Assay (MPA) 50–3
- Ninhydrin sweat test 179
- Principal Therapeutic Intervention Target 73
- Rivermead score 152
- Sternocleidomastoid Test (SCM) 52
- Tardieu Scale 148, 150
- Thomas test 144, 145
- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) 100
- Unilateral Brow Injection Test (UBI) 50
- Wartenburg Pendulum Test 148, 151
- Ewing protocol 310
- exocrine cells, response to botulinum toxin A 15
- exocytosis 10, 15, 17, 37
- Extensor Digitorum Brevis Test (EDB) 52
- extraocular muscles, treatment with botulinum toxin 28
- extropia 264, 265
- eye brow. *See* brow
- eye conditions. *See* amblyopia; apraxia of eye opening; blepharospasm; diplopia; estropia; extropia; glaucoma; hyperlacrimation; nystagmus; ptosis; strabismus (squint); thyroid eye disease
- eyelid position disorders. *See* ptosis
- face, treatment of
 - brow 335, 338
 - bunny lines 338–9
 - crow's feet (lateral canthal rhytids) 337–9
 - downturned smile 342–3
 - glabellar. *See* glabellar area
 - forehead 334–7
 - “gummy smile” 342
 - lips 341
 - lower face 339–44
 - marionette lines 340, 347
 - mentalis (golf ball chin) 343
 - neck wrinkles and lines 343–4
 - rhytids 330, 335, 337–9, 341, 343, 345–7
- facial
 - movement disorders
 - 273–5. *See also* blepharospasm; hemifacial spasm; palsy, post facial; myokymia
 - nerve palsy 208
 - scars, botulinum toxin treatment for 279
 - tics 3
 - wrinkles (hyperkinetic lines) 7, 28, 231, 331. *See also* glabellar area

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**380****Index**

- familial dysautonomia 204
- fenfluramine 86
- fibromyalgia 64, 252
- finasteride 294
- flecainide 86
- fluoxetine 354
- flumazenil 132
- focal dystonias 28, 64, 82, 365–6. *See also* dystonia
- focal muscle spasm 29
- forehead wrinkles 334–7
- Frey's syndrome (gustatory sweating) 189–91, 205, 207, 208, 213
- Frontalis-Type A Test (F-TAT) 50–2
- Fugl-Meyer Motor Assessment Score 152
- Functional Independence Measure 150
- gabapentin 137, 247, 361, 368
- galanin 175
- gall bladder. *See* pancreato-biliary system
- gamma-aminobutyric acid (GABA) 15, 88–9, 135
- gamma-hydroxybutyric acid (GHB) 354
- ganglioside 12
- gastrointestinal tract
 - botulinum toxin for disorders of 22, 45, 64, 72, 283, 311
 - disorders of 297, 318
 - pelvic floor dysfunction 299, 311–14
 - physiology of 300–3. *See also* anal; pancreato-biliary system
- gentamicin 75
- geste antagoniste 83
- glabellar area
 - adjunctive fillers for 330
 - anatomy 331–2
 - botulinum toxin type A use for 28, 65, 72
 - brow treatment 331
 - diffusion of botulinum toxin during treatment 330, 331, 333
 - injection techniques for 35, 333
 - lines 332, 333, 339, 343, 344
 - rhytids 330
 - side effects of treatment of 334
- glaucoma 268
- gluoxetine 177
- glutamate 15, 135, 231
- glutamic acid decarboxylase (GAD) 355
- glycopyrronium bromide (glycopyrrolate) 180, 207
- Good Manufacturing Practice (GMP) 31, 32
- guanethidine 11
- haemagglutinin (HA) 9, 21, 29, 36
- haloperidol 89
- Hall, Ivan 33
- handling of botulinum toxin 10
- headache
 - acute 233
 - botulinum toxin for 231, 236–9
 - chronic daily (CDH) 14, 233–6, 238, 239
 - chronic tension 64, 231, 236
 - management of 233
 - medication for 233
 - migraine. *See* migraine headache
- health care systems 66, 75, 129, 185
- Health Related Quality of Life Measures (HR-QoL) 275
- hemifacial spasm
 - as indication for botulinum toxin treatment 263
 - botulinum toxin treatment of 3, 4, 28, 64, 72, 276–7
 - definition of 276
 - management of 6
- hemithorax 182
- hepatitis 136
- Hirschsprung's disease 316
- Horner's Syndrome 182
- Hospital Anxiety and Depression Scale (HAD) 252
- Huntington's disease 86, 350, 353
- hyaluronic acid 345–7
- hyaluronidase 329
- hyperhidrosis 6
 - anesthesia for injections 182, 187, 188, 194
 - antiperspirant use for 180
 - axillary 181–4
 - botulinum toxin for 22, 28, 35, 72, 180, 182–8, 190, 191, 193, 213, 231, 329
 - classification of 176, 177
 - compensatory 181, 182, 191, 193
 - definition and symptoms 176–8
 - diagnosis 177, 193
 - drugs affecting 177, 180
 - facial 189–91
 - focal (localized) 64, 65, 177
 - generalized 176
 - guidelines for treating 75
 - impact on patients 178
 - inguinal 191
 - measurement of 179–80
 - nerve block for 185
 - pain during treatment for 185
 - palmar 181, 184–8, 194
 - plantar 181, 188–9, 194
 - prevalence 178
 - resistance to hyperhidrosis 178, 194
 - surgical treatment for 181
 - therapy 180–2
 - treatment side effects 180, 181, 184, 189, 193, 194. *See also* anhidrosis; chromhidrosis; sweating
- Hyperhidrosis Disease Severity Scale (HDSS) 179, 180
- Hyperhidrosis Impact Questionnaire (HHIQ) 179
- hyperkinetic lines. *See* facial wrinkles (hyperkinetic lines)
- hyperlacrimation 22, 64, 279. *See also* tears
- hypersalivation
 - absolute 204, 205
 - and familial amyloid polineuropathy 204
 - botulinum toxin for 6, 22
 - definition of 201

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**381****Index**

- from autosomal-recessive disorder 204
- from rabies 204
- from mercurial poisoning 204
- relative. *See* drooling
- transient 204. *See also* saliva; salivary gland
- hypophonia 352
- immunoassays for botulinum toxin 30, 45
- immuno-resistance to botulinum toxin
 - from antibodies 45–54, 92, 93,
 - 194. *See also* immuno-resistance to botulinum toxin
 - development of 47–50, 87, 142, 182, 191
 - prevalence of 45, 80
 - primary resistance 45–7, 49, 92, 93
 - secondary resistance 29, 45, 47, 48, 51, 52, 74, 92, 142, 194
- immunoprecipitation assay (IPA) 51–53
- incontinence 290, 291, 294, 306,
 - 310. *See also* bladder, urinary: incontinence
- inositol triphosphate 303
- insulin secretion 38
- intravenous regional anesthesia (IVRA) 187, 188
- iontophoresis for hyperhidrosis 181, 194
- Ipsen, Ltd. 4, 28, 29, 59, 288, 309, 313
- Isaac's syndrome 277
- Isolagen® 345
- isoniazid 361
- Japan, botulinum toxin type A from 29
- Jebens Taylor Hand test 152
- Kerner, Justinus 1, 201, 211
- kernicterus 85
- ketamine 262, 263
- Lambert-Eaton syndrome 74, 255
- laryngeal dystonia. *See* dystonia: laryngeal
- laser surgery 72
- Lattinen test 252
- Lesch Nyhan syndrome 85
- leukemia 176
- levetiracetam 354
- levodopa 86, 89
- lidocaine 187, 252, 289, 329, 330
- Likert Scale 152
- lipid disorders 85
- lymphoma 176
- magnetic resonance imaging (MRI) 251, 353, 365
- malaria 176
- Medicines Control Agency (MCA) 4, 28
- Meige syndrome 64, 275
- metoclopramide 86, 344
- methylamine – lysosomotropic agents 15
- methylphenidate 351
- methylprednisolone 252
- mexiletine 89
- micturition 283, 284, 287
 - anatomy and physiology
 - 282–6. *See also* bladder, urinary
- mizolam 132
- migraine headache
 - botulinum toxin for 28, 64, 237, 239
 - disability due to 229
 - economic costs 229
 - episodic 231–3
 - prevalence of 229
 - prophylactic treatment 229, 230
 - symptoms 229, 230
 - therapies 229
 - therapeutic guidelines for treatment 230
 - transformed 231, 233, 234
- Minor starch iodine test 179, 182, 183, 188, 189, 191, 208
- monoclonal antibody-based immunoassay 53
- morphine 38, 247
- Mouse Diaphragm Assay (MDA) 47, 50, 52, 53. *See also* Mouse Protection Assay (MPA)
- mouse lethality assays 30
- mouse LD₅₀ 30, 32, 60
- Mouse Protection Assay (MPA)
 - 50–3. *See also* Mouse Diaphragm Assay (MDA)
- MRC Scale 149
- Mr. Spock brow 336
- multiple sclerosis 5, 64, 73, 122, 128, 136–8, 141, 142, 144, 146, 148, 205, 273, 289, 358, 361
- muscle
 - atrophy 3, 74
 - relaxants 247
 - smooth 302
 - spasm 64
 - stimulation 71
 - tone 150, 302
 - trigger points 253–6
- myalgia 69
- myasthenia gravis 74, 95, 205, 255
- mycophenolate 54
- Myobloc® (USA). *See* botulinum toxin type B
- myoclonus
 - aetiology of 353
 - botulinum toxin for 7, 352–5
 - classifications of 352–4
 - medications for 354
- myofascial pain syndrome (MPS) 64, 252, 253
- myokymia 65, 277
- Naphcon A 334
- naproxen 177
- neck
 - back. *See* back pain
 - pain 28, 94, 245. *See also* back pain
 - posture 87
 - spasms 46
- nerve
 - cultured 19
 - ecto-acceptors 10, 12, 14
 - endplate potentials 10
 - peripheral, dysfunction in 75
 - remodelling 10
 - responses to botulinum toxin 15,
 - 17. *See also* botulinum toxin: mechanism of action

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**382** Index

- nerve (cont.)
 - sprouting 10, 17, 125
 - stimulation 71, 90, 91
 - terminals 12, 13
 - toxin-susceptible cholinergic 13
- neuroacanthocytosis 350
- Neurobloc®. *See* botulinum toxin type B
- neurokinin A 301
- neuroleptics 350
- neuromuscular paralysis. *See* botulinum toxin:
 - mechanism of action
- neurons. *See* nerve
- neuropeptides 301
- Ninhydrin sweat test 179
- nitric oxide (NO) 297, 299–301, 306
- nonsteroidal anti-inflammatory drugs (NSAIDs) 232, 246, 247
- non-toxic, non-haemagglutinin protein (NTNH) 36
- norepinephrine 175
- noradrenergic excitatory responses 12
- nystagmus 3, 64, 272–3
- occupational cramps 7
- Oculinum, Inc. 4, 28
- oesophageal reflux 64
- olanzapine 361
- opioids 177, 246, 247
- ophthalmologic disorders. *See* amblyopia;
 - blepharospasm; diplopia; esotropia; exotropia; glaucoma; hyperlacrimation; ptosis; strabismus (squint); thyroid eye disease
- oscillopsia 64
- Oswestry Questionnaire 252
- oxybutynin 181
- pain
 - analgesics for. *See* analgesics
 - anesthesia for 184, 185, 187, 188, 220
 - back. *See* back pain
 - biliary 316
 - botulinum toxin for 231, 236–7, 250
 - cervical dystonia 82
 - chronic 38–9, 294
 - control 188
 - intravenous regional anesthesia (IVRA) 187, 188
 - models 39
 - morphine treatment for 38
 - neck. *See* pain
 - neurogenic 38
 - scales 363
 - signals 38
 - spinal 243, 257. *See also* back pain; neck pain; myofascial pain syndrome (MPS)
- palatal myoclonus 112, 120
- palsy, post facial 6, 277
- pancreas. *See* pancreato-biliary system
- pancreato-biliary system
 - bile flow in 294
 - botulinum toxin for disorders of 317
 - disorders of 316–17
 - function changes from botulinum toxin 38
 - sphincter of Oddi dysfunction 316–18. *See also* sphincter: of Oddi
- paracetamol 246, 247
- paralysis, muscle 1, 12, 14, 15, 17–21, 45
- Parkinson's disease
 - botulinum toxin for 7, 357–60
 - constipation 311, 314, 358
 - deep brain stimulation for 361
 - dopamine replacement therapy 357
 - drooling 6, 204, 216, 357
 - dystonia 357, 365
 - freezing of motion 358–9
 - hypersalivation in 204
 - muscle spasms 358
 - ophthalmologic disorders in 357–8
 - rigidity 359–60
 - pallidotomy for 90
 - tremor 360–2
- patient
 - assessment 70, 97–8, 131, 329
 - follow up visits 100
 - informed consent and consent forms 69, 262, 328, 329, 341
 - open label flow chart 62
 - preparation for botulinum toxin 69–70, 96
- peptides 15
- pharynx, disorders of 112
- phenol 65, 134, 139–43
- photophobia 229, 338
- physiotherapy 87, 146, 152
- physostigmine 177
- piracetam 354
- pneumothorax 182
- poliomyelitis 74
- poly L lactic acid (Sculptra®) 346, 347
- primidone 361
- Principal Therapeutic Intervention Target 73
- propranolol 177
- prostate-specific antigen (PSA) 295, 297
- proteases 36
- ptosis 6, 182, 189, 202, 264, 267, 272, 273, 275–9, 330, 333, 334, 338
- Quality Control testing 31, 32. *See also* botulinum toxin: manufacturing processes
- Radiesse® 345, 346
- radish calf 344–5
- randomized control trials (RCTs) 153, 154
- rectoanal inhibitory reflex (RAIR) 300
- Restylane® 330, 338, 343
- rigidity 65
- risperidone 351
- Rivermead score 152
- safety margin for botulinum toxin 74
- saliva
 - enzymes 202
 - function 201
 - measurement 206
 - production rate 201, 205, 211

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**383 Index**

- salivary gland
 - atrophy 202, 213
 - autonomic neural control 202, 203
 - calculi 201
 - effect of botulinum toxin on 212
 - lingual 202
 - parotid 201–3, 208, 212, 214–18, 235
 - saliva production by 202
 - sublingual 202, 212, 214–17
 - submandibular 201–3, 208, 212, 214–19
- scopolamine 208
- Sculptra® 346
- sensory trick 83
- serotonin (5HT) 135
- serotonin reuptake inhibitors 177
- serotypes of botulinum toxin
 - cross-reactivity between 49
 - differences between 9, 29, 39, 59, 65, 93
 - efficacy conversion ratio between 60, 62
 - unidentified 12. *See also specific serotypes*
- sialorrhoea. *See drooling*
- silicone, as a filler 345–7
- slewed jaw dystonia 112, 119–20
- snake venom 262, 263
- SNAP-25 10, 17–19, 21, 37, 59. *See also* SNARE proteins
- SNARE proteins 10, 17, 21, 37. *See also* SNAP-25; syntaxin; synaptobrevin
- snoring 29
- sodium valproate 354
- SPASM Consortium 122
- spasmodic dysphonia. *See* dystonia: laryngeal
- spasmodic torticollis. *See* cervical dystonia
- spastic co-contraction 124
- spastic dystonia 122–6, 129, 131. *See also* spasticity
- spasticity
 - botulinum toxin treatment for 69, 123, 127, 134, 141, 143, 146, 155
 - chronic 73, 76, 146
 - classification 123, 125, 126
 - definitions of 122–4
 - dosages of botulinum toxin for 60, 143
 - drugs 131–4
 - epidemiology 127–8
 - history of treatment of 3
 - health impact of 127
 - indications for treatment of 76, 133
 - limb 3, 74, 151
 - management of 5, 6, 62, 68, 72, 75, 123, 128–34, 147, 153, 155
 - muscles typically involved in 163–71
 - non-responsive patients 142
 - pain treatment for 231, 236–7
 - pathophysiology of 123–5
 - patient assessment 131, 133
 - post-injection care in 146
 - prevalence 127, 128
 - surgical treatment 134
 - symptoms of 123, 126
 - treatment cost 127, 128
 - treatment principles 131
 - treatment sheet 172
- sphincter
 - external anal (EAS) 283, 298, 301, 309–11, 314
 - internal anal (IAS) 283, 297, 299, 305, 306, 309, 310, 316
 - of Oddi 283, 316–18. *See also* pancreato-biliary system
- sphincterotomy 305, 317, 318
- spinal
 - cord injury 64, 122, 136, 137, 144, 284, 287, 289, 290
 - fusion
 - stenosis 249
- squint. *See* strabismus (squint)
- Sternocleidomastoid Test (SCM) 52
- strabismus (squint)
 - as cause of abnormal neck posture 87
 - botulinum toxin treatment 3, 5, 27, 28, 64, 263–9
 - classifications 3, 265–73
 - contraindications of treatment for 264
 - Dysport® use for 28
 - early treatment of 3, 4, 262, 263
 - indications for 265–73
 - management of 6
 - recurrence of 264
 - surgery for 267
 - treatment side effects 264. *See also* estropia; extropia
- stiff person syndrome 7, 65, 87, 355–7
- stroke 64, 122, 136, 358
- substance P 15, 231, 301
- succinylcholine 60
- surgery. *See specific disorder*
- sweat
 - glands 175, 176
 - production 176
- sweating
 - acetylcholine's role in 175, 176
 - and catecholamines 175, 176
 - compensatory 181, 193
 - control of 175. *See* hyperhidrosis
 - function of 175
 - gustatory (Frey's syndrome) 6, 182, 189–91, 205, 207, 208, 213
 - role of hypothalamus in 175. *See also* hyperhidrosis: botulinum toxin for
- synaptic transmission mechanism 10
- synaptobrevin 10, 17, 19, 21, 37. *See also* SNARE proteins
- synaptotagmin 12
- syntaxin 9, 10, 17, 21, 37. *See also* SNARE proteins
- tachykinins 301
- tamsulosin 294, 295
- Tardieu Scale 148, 150
- tardive dyskinesias 89
- target organ selection 70–2, 96–7, 142. *See also* electromyography guidance; ultrasonography
- tears, botulinum toxin treatment for 279. *See also* hyperlacrimation

Cambridge University Press

978-0-521-83304-2 - Clinical Uses of Botulinum Toxins

Anthony B. Ward and Michael P. Barnes

Index

[More information](#)**384** Index

- terazosin 294, 295
- tetanus and tetanus toxin 40, 49
- tetrabenazine 89, 351
- therapeutic ratio
 - definition of 35
- Thomas test, for psoas 144, 145
- 3,4 aminopyridine 74
- thyroid eye disease 270
- tics 349–52
 - botulinum toxin for 65, 350–2
 - definition of 349
 - management 350–1
 - motor 350–2
 - natural history of 350
 - side effects from treatment of 352
 - vocal 352. *See also* Tourette's syndrome
- tizanidine 135, 137, 154, 356, 368
- toe spread reflex (TSR) 21
- tongue dystonia 112, 113, 116–18
- topiramate 361
- Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) 100
- torticollis
 - spasmodic 28
- Tourette's syndrome 65, 349–52
- training for botulinum toxin administration 75–6
- tremor
 - botulinum toxin for 7, 361–4
 - classification of 354, 360
 - definition of 360
 - drug resistant 361
 - essential 64
 - forms of 64, 82, 362, 364
 - Parkinson's disease 360
- tricyclic antidepressants 177, 230, 247, 351
- trihexyphenidyl 208
- triptan medications 229, 232
- Tsui scale 363
- tuberculosis 176
- ultrasound therapy 248
- ultrasonography 71, 72, 143, 213, 219–21, 253, 297
- Unilateral Brow Injection Test (UBI) 50–2
 - upper limb focal spasticity 28, 73
- urine. *See* bladder, urinary; micturition
- urinary bladder. *See* bladder, urinary
- uroflowmetry 292, 293, 295–7. *See also* bladder, urinary; urogenital tract disorders
- urogenital tract disorders
 - benign prostatic hyperplasia (BPH) 283, 294–7
 - botulinum toxin for 296, 297, 299
 - detrusor-sphincter dyssynergia (DSD) 284–91
 - erectile dysfunction 294
 - female sexual dysfunction 298
 - idiopathic detrusor overactivity (sensor urge) 291
 - neurogenic detrusor overactivity 283, 289–91
 - neurotransmitters and 284
 - rectocele 314, 315
 - reflexes and 287. *See also* bladder, urinary
- urethral syndrome 64
- vaccines 2, 6, 40
- vaginismus 64, 298
- van Emengem, Pierre 2
- vasoactive intestinal peptide (VIP) 175, 301
- venlafazine 177
- vesicle associated membrane protein (VAMP). *See* synaptobrevin
- viral encephalitis 85
- Visual Analog Scale (VAS) 206, 252
- Wartenburg Pendulum Test 148, 151
- WeMove 62
- Western blot assay (WBA) 50, 51, 53
- whiplash 249, 252–3
- Wilson's disease 85, 361
- World Health Organization 229
- wrinkles. *See* face: treatment of
- writer's cramp. *See* cramps: writer's
- Xeomin 3, 5, 59, 76. *See also* botulinum toxin type A
- Zonisamide 354
- Zyderm® 345, 346